EG3-13512-35314
3 vaccinations
1 coded response
6 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 640 / MO
- Registered
- 2021-02-26
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-05
Dose 1 — Pfizer-BioNTech
-
2021-02-26
Registered in v-safe
-
2021-02-26
Dose 2 — Pfizer-BioNTech
- 2021-02-26
- 2021-02-28
-
2021-03-12
Survey response — day 14, dose 2MedDRA: Chills, Fatigue, Pain, Pyrexia — Feeling: Good · Be unable to do your normal daily activitiesFree text: Fever, aches and chills, very tired. Symptoms started 18 hours after shot and ended within 12 hours of starting.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-03-12
Report sent to call center — day 14, dose 2Be unable to do your normal daily activities1 call case(s)
- 2021-08-27
-
2021-12-15
Dose 3 — Pfizer-BioNTech
- 2022-02-26
- 2022-06-15
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-05 | Pfizer-BioNTech | |
| 2 | 2021-02-26 | Pfizer-BioNTech | |
| 3 | 2021-12-15 | Pfizer-BioNTech | No |
Call center
1 call center case
1 priority 2/3 (triaged and no follow up)
Free text
Release 5 — day 14, dose 2
Symptoms: Fever, aches and chills, very tired. Symptoms started 18 hours after shot and ended within 12 hours of starting.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Chills | ✓ | ✓ | ✓ |
| SD | Fatigue | ✓ | ✓ | ✓ |
| SD | Pain | ✓ | ✓ | ✓ |
| SD | Pyrexia | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release